These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1298 related articles for article (PubMed ID: 20351327)

  • 1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
    Aupérin A; Le Péchoux C; Rolland E; Curran WJ; Furuse K; Fournel P; Belderbos J; Clamon G; Ulutin HC; Paulus R; Yamanaka T; Bozonnat MC; Uitterhoeve A; Wang X; Stewart L; Arriagada R; Burdett S; Pignon JP
    J Clin Oncol; 2010 May; 28(13):2181-90. PubMed ID: 20351327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
    Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
    Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.
    Burdett S; Pignon JP; Tierney J; Tribodet H; Stewart L; Le Pechoux C; Aupérin A; Le Chevalier T; Stephens RJ; Arriagada R; Higgins JP; Johnson DH; Van Meerbeeck J; Parmar MK; Souhami RL; Bergman B; Douillard JY; Dunant A; Endo C; Girling D; Kato H; Keller SM; Kimura H; Knuuttila A; Kodama K; Komaki R; Kris MG; Lad T; Mineo T; Piantadosi S; Rosell R; Scagliotti G; Seymour LK; Shepherd FA; Sylvester R; Tada H; Tanaka F; Torri V; Waller D; Liang Y;
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD011430. PubMed ID: 25730344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
    Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
    J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence.
    Pöttgen C; Eberhardt W; Stamatis G; Stuschke M
    Oncotarget; 2017 Jun; 8(25):41670-41678. PubMed ID: 28415831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
    Pignon JP; Tribodet H; Scagliotti GV; Douillard JY; Shepherd FA; Stephens RJ; Dunant A; Torri V; Rosell R; Seymour L; Spiro SG; Rolland E; Fossati R; Aubert D; Ding K; Waller D; Le Chevalier T;
    J Clin Oncol; 2008 Jul; 26(21):3552-9. PubMed ID: 18506026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.
    Aupérin A; Le Péchoux C; Pignon JP; Koning C; Jeremic B; Clamon G; Einhorn L; Ball D; Trovo MG; Groen HJ; Bonner JA; Le Chevalier T; Arriagada R;
    Ann Oncol; 2006 Mar; 17(3):473-83. PubMed ID: 16500915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
    Bradley JD; Bae K; Graham MV; Byhardt R; Govindan R; Fowler J; Purdy JA; Michalski JM; Gore E; Choy H
    J Clin Oncol; 2010 May; 28(14):2475-80. PubMed ID: 20368547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
    Pezzetta E; Stupp R; Zouhair A; Guillou L; Taffé P; von Briel C; Krueger T; Ris HB
    Eur J Cardiothorac Surg; 2005 Jun; 27(6):1092-8. PubMed ID: 15896624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
    Rossi A; Di Maio M; Chiodini P; Rudd RM; Okamoto H; Skarlos DV; Früh M; Qian W; Tamura T; Samantas E; Shibata T; Perrone F; Gallo C; Gridelli C; Martelli O; Lee SM
    J Clin Oncol; 2012 May; 30(14):1692-8. PubMed ID: 22473169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
    Pradier O; Lederer K; Hille A; Weiss E; Christiansen H; Schmidberger H; Hess CF
    J Cancer Res Clin Oncol; 2005 Apr; 131(4):261-9. PubMed ID: 15616830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
    Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A phase II study of weekly cisplatine plus oral vinorelbine with concomittant radiotherapy in non-dependent elderly patients with localized inoperable non small cell lung carcinoma (Essai GFPC 08-06, Raccosa)].
    Locher C; Pourel N; Marin B; Vergnenègre A;
    Rev Mal Respir; 2011 Jan; 28(1):58-65. PubMed ID: 21277475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
    NSCLC Meta-analysis Collaborative Group
    Lancet; 2014 May; 383(9928):1561-71. PubMed ID: 24576776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of radiotherapy and chemotherapy in locally advanced NSCLC.
    Kepka L; Sprawka A; Casas F; Abdel-Wahab S; Agarwal JP; Jeremic B
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1389-403. PubMed ID: 19827998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.